Menu

CME Corner

Active Programs

Novel Targeted Agents in the Management of Recurrent Advanced Ovarian Cancer

Ovarian cancer is the fifth most common cause of cancer death in women in the United States. The majority of patients with ovarian cancer experience disease recurrence and receive second-line and sometimes several lines of therapy. Recurrent ovarian cancer is often resistant to chemotherapy, thus limiting the treatment options. Advances in technology and medical research have identified VEGF and P ...

  • Online Presentation Online Presentation
  • ACCME

Nursing Management of Treatment-Related Side Effects in Metastatic Prostate Cancer

Treatment for prostate cancer has expanded and improved in recent years, but many patients continue to live with the long-term sequelae of the disease and treatment-related side effects. There are numerous treatment options available for both hormone-sensitive and castration-resistant metastatic prostate cancer, and oncology nurses must be knowledgeable about these and their wide range of adverse ...

  • Online Presentation
  • AANP
  • ACCME
  • ANCC

Expired Programs

Evolving Standards of Care in Metastatic Prostate Cancer

For patients with metastatic prostate cancer (mPRCA), the number of metastases has prognostic and therapeutic implications. Clinicians who treat patients with mPRCA need to recognize patients with oligometastatic prostate cancer and be aware that management of patients with fewer than 5 metastases is different from that of patients with polymetastatic disease. Recommendations for the initial manag ...

  • Online Presentation Online Presentation
  • ACCME

Metastatic Colorectal Cancer: Applying Evidence-based Recommendations for Evaluation and Management

Colorectal cancer is the third most common cancer in men and women. Current evidence-based guidelines recommend that all metastatic colorectal tumors be tested for RAS mutations (both KRAS and NRAS) and BRAF mutations, as the presence of such mutations has implications for treatment. Clinical practice is variable, however, and many patients do not receive guideline-based care. This activity will e ...

  • Online Presentation Online Presentation
  • ACCME
  • ANCC

The Pharmacist's Role in Advanced or Metastatic Breast Cancer

Cyclin-dependent kinase (CDK) 4/6 inhibition significantly prolongs progression-free survival (PFS) in patients with metastatic breast cancer (mBRCA) whose disease progresses on endocrine therapies. This activity will examine emerging evidence and best practices supporting the use of CDK4/6 inhibitors. This activity was originally presented as a webcast series on the following 4 dates: February ...

  • Online Presentation
  • ACPE
Main Menu
EDITOR'S PICKS